Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (296)	5/30/1998 3:46:00 PM
From: John Dwyer	Respond to of 4474

ARGENT continues to move along. This is a really exciting program, IMO. They have really enjoyed tremendous success with this system in preclinical studies. I truly feel that very few people realize just how powerful this technology is... perhaps because of the past failures with gene therapy. I see they are having continued success expanding cell populations in vitro. They report here the proliferation of hematopoietic cells for over three months!! The cells remained active in animals as well... remarkable. This has potential applications in skin grafts, bone marrow transplants, etc. The annual report talks about growing new limbs... I'll believe that when I see it... still, grafts and transplants represent another broad, gigantic market. So, over the next six months we should see at least one major partnership, probably from a signal transduction program, and the beginning of the ARGENT trials. An osteo drug (Src inhib) should be in the clinic next year. I think things are looking real good for ARIA right now. I am still accumulating at prices around $4. John